美洲 · 综合新闻 · Toronto Star
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
详细摘要
Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to improving ...
MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.thestar.com)
/https://i.s3.glbimg.com/v1/AUTH_da025474c0c44edd99332dddb09cabe8/internal_photos/bs/2026/c/0/mjNG4wQRiHBz4p2YvC8Q/116941896-files-this-photograph-taken-on-december-15-2024-shows-the-narva-ivangorod-crossing-at-the.jpg)
